RT Journal Article
SR Electronic
T1 Evaluation of determinants of the serological response to the split-inactivated influenza vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.07.21264416
DO 10.1101/2021.10.07.21264416
A1 Wu, Shaohuan
A1 Ross, Ted M.
A1 Carlock, Michael A.
A1 Ghedin, Elodie
A1 Choi, Hyungwon
A1 Vogel, Christine
YR 2021
UL http://medrxiv.org/content/early/2021/10/11/2021.10.07.21264416.abstract
AB The seasonal influenza vaccine is only effective in half of the vaccinated population. To identify determinants of vaccine efficacy, we used data from >1,300 vaccination events to predict the response to vaccination measured as seroconversion as well as hemagglutination inhibition (HAI) levels one year after. We evaluated the predictive capabilities of age, body mass index (BMI), sex, race, comorbidities, prevaccination history, and baseline HAI titers, as well as vaccination month and vaccine dose in multiple linear regression models. The models predicted the categorical response for >75% of the cases in all subsets with one exception. Prior vaccination, baseline titer level, and age were the strongest determinants on seroconversion, all of which had negative effects. Further, we identified a gender effect in older participants, and an effect of vaccination month. BMI played a surprisingly small role, likely due to its correlation with age. Comorbidities, vaccine dose, and race had negligible effects. Our models can generate a new seroconversion score that is corrected for the impact of these factors which can facilitate future biomarker identification.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCV and TR acknowledge funding by the US National Institutes of Health (R35GM127089 and 75N93019C00052/NH/NIH HHS/United States). HC was supported in part by National Medical Research Council, Singapore (NMRC/CG/M009/2017). Cohort data was obtained from a study supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002378. EG was supported in part by the Division of Intramural Research (DIR) of the NIAID/NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study procedures, informed consent, and data collection documents were reviewed and approved by the Institutional Review Board of the University of Georgia (IRB #3773)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://github.com/sw5019/Fluvacc-metadata-project